Presentation Details: Title: Dextromethorphan/Quinidine for Treatment of Pseudobulbar Affect
in Patients with Dementia: Treatment Effects by Concomitant Antidepressant Use in a 12-week Open-Label Trial (PRISM II) Presentation Number: 04-09-06 Time: Wednesday, July 22, 4:15 p.
NUEDEXTA Indication and Important Safety Information NUEDEXTA is indicated for the treatment of pseudobulbar affect
AVANIR's lead product candidate, Zenvia, has completed a confirmatory Phase III trial in the treatment of pseudobulbar affect
Title: Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect
in Patients with Alzheimer's Disease/Dementia: PRISM-II Poster Number: M1334WIP Presentation Date/Time: Monday, October 13, 2014; 5:30 p.
AVP-923 at the 20/10 mg dose strength is approved by the FDA for the treatment of pseudobulbar affect
(PBA) and marketed under the trade name NUEDEXTA (see description below).
Zenvia has completed a confirmatory Phase III trial in the treatment of pseudobulbar affect
(PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain.
These initial data showing reduced symptoms of pseudobulbar affect
(PBA) in patients with PBA secondary to Alzheimer's and dementia are consistent with the benefits we saw in the pivotal phase III study, in PBA patients with ALS and MS, and provide further evidence that NUEDEXTA may offer relief from the debilitating episodes of PBA," said Joao Siffert, MD, chief medical officer at Avanir.
Title: Prevalence and Correlates of Pseudobulbar Affect
(PBA) Symptoms in Nursing Home Residents Poster Number: 45786 Presentation Date/Time: Wednesday, July 16, 2014; 11:45 a.
NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect
(PBA), a distressing neurological condition characterized by uncontrollable laughing or crying, will be presented at the following conferences in June.
NASDAQ: AVNR) today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia[TM] (dextromethorphan/quinidine) in the treatment of pseudobulbar affect
(PBA) in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.